MED7 Life Sciences
Strategy. Commercialisation. Growth.
Senior executive advisory and consultancy for MedTech, diagnostics and digital health companies navigating growth, international expansion and commercial transformation.Supporting leadership teams from strategy through to execution.
What we do
Turning strategy into commercial results
MED7 works with Life Sciences businesses at critical points of growth and change. We bring extensive international operating experience to complex strategic and commercial challenges — combining board-level thinking with practical execution.
Our work spans established multinational businesses, high-growth companies and emerging technologies entering new markets.
Commercial Strategy & Go-to-Market
Market prioritisation, GTM strategy, channel design, pricing, commercial models and launch planning.
International Expansion
Market entry, distributor strategy, direct-market development, localisation and international operating models.
Business Development & Strategic Partnerships
Partner identification, strategic alliances, licensing, OEM/ODM opportunities and commercial due diligence.
Commercial Transformation
S&OP, commercial effectiveness, organisational design, performance management and distributor optimisation.
Market Access & Healthcare Systems
Reimbursement strategy, market access pathways, healthcare stakeholder engagement and value propositions.
Executive & Board Advisory
Independent strategic support to CEOs, boards, investors and leadership teams navigating major commercial decisions.
Built on operating experience, not just advisory experience
MED7 brings experience gained from senior international leadership roles across the Life Sciences sector, including responsibility for businesses and teams across Europe, Asia-Pacific and global markets.
We understand the difference between recommending a strategy and being accountable for delivering one.
From innovation to international scale
We particularly support businesses facing questions such as:
- How should we prioritise international markets?
- Should we build direct, distributor or hybrid commercial models?
- How do we turn a promising technology into a scalable commercial proposition?
- Where should we invest — and where should we stop investing?
- How should our product, market access and commercial strategies fit together?
- Which partnerships could accelerate growth?
- How do we build the organisation required for the next stage of scale?
but the number one difference is
experience
get in touch
Contact us
We are located in London but serve clients globally.
